COVID-19-ის ვაქცინა: განსხვავება გადახედვებს შორის

|'''[[Pfizer–BioNTech COVID-19 vaccine]]''' <small>(Comirnaty)</small><wbr /><ref name="hcreg">{{#invoke:Cite web| |date=9 December 2020|title=Regulatory Decision Summary – Pfizer–BioNTech COVID-19 Vaccine|url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00730|access-date=9 December 2020|publisher=Health Canada, Government of Canada}}</ref><ref name="NCT04368728">{{#invoke:Cite web| |title=Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04368728 |website=[[ClinicalTrials.gov]] |id=NCT04368728 |date=30 April 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011084828/https://clinicaltrials.gov/ct2/show/NCT04368728/ }}</ref><ref name="EudraCT-2020-001038-36">{{#invoke:Cite web| |title=A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |website=EU Clinical Trials Register |publisher=European Union |id=[[EudraCT]] 2020-001038-36 |date=14 April 2020 |access-date=22 April 2020 |archive-url=https://web.archive.org/web/20200422111024/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |archive-date=22 April 2020 |url-status=live}}</ref><br />[[BioNTech]], [[Pfizer]]

|2 დოზაdoses<br />3–4 კვირაweeks<wbr /><ref>{{citeCite news | vauthors = Farge E, Revill J |date=5 January 2021 |title=WHO recommends two doses of Pfizer COVID-19 vaccine within 21–28 days |work=Reuters |location=Geneva |url=https://www.reuters.com/article/us-health-coronavirus-who/who-recommends-two-doses-of-pfizer-covid-19-vaccine-within-21-28-days-idUSKBN29A25G |work=Reuters |location=Geneva |access-date=5 March 2021 |vauthors=Farge E, Revill J}}</ref>{{efn-la|name=who-extended-interval-rna-vaccines|Recommended interval. The second dose of the Pfizer–BioNTech and Moderna vaccines can be administered up to six weeks after the first dose to alleviate a shortage of supplies.<ref>{{citeCite news | vauthors = Keaten J |date=8 January 2021 |title=WHO: Amid short supplies, vaccine doses can be 6 weeks apart |work=Associated Press |location=Geneva |url=https://apnews.com/article/immunizations-coronavirus-pandemic-united-nations-bb16e94b0726ca810835b7a78b1f86f6 |work=Associated Press |location=Geneva |access-date=6 March 2021 |vauthors=Keaten J}}</ref><ref>{{citeCite news |date=26 January 2021 |title=COVID vaccine: Moderna shots can be 6 weeks apart, WHO says |work=Deutsche Welle |url=https://www.dw.com/en/covid-vaccine-moderna-shots-can-be-6-weeks-apart-who-says/a-56348264 |work=Deutsche Welle |access-date=6 March 2021}}</ref>}}

| data-sort-value="-70±" {{shade|align=left|valign=top|color=blue|max=70|70|{{val|-70|10°C|u=degC}}<wbr />{{efn-la|Long-term storage temperature. The Pfizer–BioNTech COVID-19 vaccine can be kept between {{Convert|-25|and|-15|C|F|abbr=}} for up to two weeks before use, and between {{Convert|2|and|8|C|F|abbr=}} for up to five days before use.<ref>{{citeCite press release |date=25 February 2021 |title=Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer–BioNTech COVID-19 Vaccine |date=25 February 2021 |publisher=[[Food and Drug Administration]] (FDA) |url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-allows-more-flexible-storage-transportation-conditions-pfizer |publisher=[[Food and Drug Administration]] (FDA) |access-date=5 March 2021}}</ref><ref name="Pfizer–BioNTech COVID-19 Vaccine EUA fact sheet">{{#invoke:Cite web| | title=Pfizer–BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers | publisher=Pfizer | date=25 February 2021 | access-date=25 February 2021 | url=https://www.fda.gov/media/144413/download | format=PDF}}</ref>}}<br />([[ULT freezer|ULT]])}}

|status=Positive results from an interim analysis were announced on 18 November 2020<ref>{{citeCite press release |title= Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints |urldate=18 November 2020 |publisher=Pfizer |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine |publisher=Pfizer |date=18 November 2020}}</ref> and published on 10 December 2020 reporting an overall efficacy of 95%.<ref name="BNT162b2 Vaccine">{{citeCite journal |display-authors=6 |vauthors = Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC | display-authors date=December 62020 | title = Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | journal = The New England Journal of Medicine | volume = 383 | issue = 27 | pages = 2603–15 | date doi= December 202010.1056/NEJMoa2034577 | pmid = 33301246 | pmc = 7745181 | doi pmid= 10.1056/NEJMoa203457733301246 | doi-access = free }}</ref><ref>{{citeCite report| |url=https://www.fda.gov/media/144337/download | format=PDF | title=FDA Review of Efficacy and Safety of Pfizer–BioNTech COVID-19 Vaccine Emergency Use Authorization Request |date=10 December 2020 |access-date=11 December 2020 |format=PDF |website=U.S. [[Food and Drug Administration]] (FDA) | date=10 December 2020 | access-date=11 December 2020}} {{PD-notice}}</ref>

|whenwhere=Jul–Nov 2020,<ref>{{citeCite news |name-list-style=vanc |date=18 November 2020 |title=Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization |publisher=Reuters |url=https://www.reuters.com/article/health-coronavirus-vaccines-pfizer/pfizer-ends-covid-19-trial-with-95-efficacy-to-seek-emergency-use-authorization-idUSL4N2HZ3VS | vauthors = Erman M |access-date=18 November 2020|publisher=Reuters|date=18 November 2020 |name-list-stylevauthors=vancErman M}}</ref><ref name="NYT-20201120" /> Germany, United States

|references=<ref name="NCT04760132" />